Human IgM antibody lysing activated lymphocytes under mediation by homologous complement
US7914790B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Jun 30, 2003 |
| Grant date | Mar 29, 2011 |
| Priority date | — |
| Expiry date | Oct 7, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/809
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM monoclonal antibody which responds specifically to activated lymphocytes and induces cell lysis under the mediation by a homologous complement. Using the human IgM monoclonal antibody responding to activated human lymphocytes, it is also intended to provide an HIV remedy, etc. characterized by lysing and eliminating activated lymphocytes to thereby treat transplantation rejection and autoimmune diseases caused by an over-response of T lymphocytes as well as HIV infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.